Results 21 to 30 of about 1,690 (152)

Efficacy and Safety of Lomitapide in Homozygous Familial Hypercholesterolaemia: A Systematic Review

Reviews in Cardiovascular Medicine, 2022
Background: Homozygous familial hypercholesterolaemia (HoFH) patients have little or no low-density lipoprotein receptor (LDLR) function. HMG-CoA (3-hydroxy-3-methyl glutaryl coenzyme A) reductase inhibitors (statins) and proprotein convertase subtilisin/
Namin Wei, Yuanhui Hu, Siyu Li, Guoxiu Liu, Nang Zhang, Qiulei Jia, Jingjing Shi, Guozhen Yuan, Huaqiang Zhai   +8 more
doaj   +1 more source

Lomitapide enhances cytotoxic effects of temozolomide in chemotherapy-resistant glioblastoma. [PDF]

JCI Insight
More than a third of patients with glioblastoma experience tumor progression during adjuvant therapy. In this study, we performed a high-throughput drug repurposing screen of FDA-approved agents capable of crossing the blood-brain barrier in order to ...
Ivanova A, Wilson TM, Ghannad-Zadeh K, Tse E, Flick R, Wu M, Das S.   +6 more
europepmc   +2 more sources

The Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr^−/− Mice with Obesity

Antioxidants, 2023
Objectives: Homozygous familial hypercholesteremia (HoFH) is a rare, life-threatening metabolic disease, mainly caused by a mutation in the LDL receptor. If untreated, HoFH causes premature death from acute coronary syndrome.
Undral Munkhsaikhan, Young In Kwon, Amal M. Sahyoun, María Galán, Alexis A. Gonzalez, Karima Ait-Aissa, Ammaar H. Abidi, Adam Kassan, Modar Kassan   +8 more
doaj   +1 more source

Lomitapide response in a cohort of patients with homozygous familial hypercholesterolemia and the potential influence of MTTP gene variants. [PDF]

Orphanet J Rare Dis
Homozygous familial hypercholesterolemia (HoFH) is a rare inherited disorder of lipoprotein metabolism caused by pathogenic variants in both alleles of key low-density lipoprotein receptor (LDLR)-mediated pathway genes, resulting in very high LDL ...
Kolovou G, Kolovou V, Anagnostopoulou K, Anastasiou G, Kalogeropoulos P, Liberopoulos E.   +5 more
europepmc   +2 more sources

A real-world analysis of Lomitapide-associated adverse events: Data from FAERS and CVAROD. [PDF]

Medicine (Baltimore)
Lomitapide, a microsomal triglyceride transfer protein (MTP) inhibitor approved for the treatment of Homozygous Familial Hypercholesterolemia (HoFH), effectively lowers LDL cholesterol but raises safety concerns, particularly regarding hepatic and ...
Liu X, Zheng Z, Chen Q, Liu Y, Li S, Wang H.   +5 more
europepmc   +2 more sources

Antibacterial activities and action mode of anti-hyperlipidemic lomitapide against Staphylococcus aureus

BMC Microbiology, 2022
Background The increasing emergence of multidrug-resistant Gram-positive bacterial infections necessitates new antibacterial agents with novel mechanisms of action that can be used to treat these infections.
Yufang Zhang, Yiying Zhang, Chengchun Chen, Hang Cheng, Xiangbin Deng, Duoyun Li, Bing Bai, Zhijian Yu, Qiwen Deng, Jie Guo, Zewen Wen   +10 more
doaj   +1 more source

Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR

Cell Death and Disease, 2022
Autophagy is a biological process that maintains cellular homeostasis and regulates the internal cellular environment. Hyperactivating autophagy to trigger cell death has been a suggested therapeutic strategy for cancer treatment.
Boah Lee, Seung Ju Park, Seulgi Lee, Jinwook Lee, Eunbeol Lee, Eun-Seon Yoo, Won-Suk Chung, Jong-Woo Sohn, Byung-Chul Oh, Seyun Kim   +9 more
doaj   +1 more source

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey

Orphanet Journal of Rare Diseases, 2021
Background Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which ...
Laura D’Erasmo, Antonio Gallo, Angelo Baldassare Cefalù, Alessia Di Costanzo, Samir Saheb, Antonina Giammanco, Maurizio Averna, Alessio Buonaiuto, Gabriella Iannuzzo, Giuliana Fortunato, Arturo Puja, Tiziana Montalcini, Chiara Pavanello, Laura Calabresi, Giovanni Battista Vigna, Marco Bucci, Katia Bonomo, Fabio Nota, Tiziana Sampietro, Francesco Sbrana, Patrizia Suppressa, Carlo Sabbà, Fabio Fimiani, Arturo Cesaro, Paolo Calabrò, Silvia Palmisano, Sergio D’Addato, Livia Pisciotta, Stefano Bertolini, Randa Bittar, Olga Kalmykova, Sophie Béliard, Alain Carrié, Marcello Arca, Eric Bruckert   +34 more
doaj   +1 more source

Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study

Frontiers in Genetics, 2022
Backgroundand aim: Autosomal recessive hypercholesterolemia (ARH) is a rare autosomal recessive disorder of low-density lipoprotein (LDL) metabolism caused by pathogenic variants in the LDLRAP1 gene.
Laura D’Erasmo, Antonina Giammanco, Patrizia Suppressa, Chiara Pavanello, Gabriella Iannuzzo, Alessia Di Costanzo, Daniele Tramontano, Ilenia Minicocci, Simone Bini, Anja Vogt, Kim Stewards, Jeanine Roeters Van Lennep, Stefano Bertolini, Marcello Arca, the Italian and European Working Group on Lomitapide in HoFH, Marcello Arca, Maurizio Averna, Stefano Bertolini, Simone Bini, Eric Boersma, Katia Bonomo, Marco Bucci, Laura Calabresi, Paolo Calabrò, Angelo Baldassare Cefalù, Jaimini Cegla, Arturo Cesaro, Sergio D’Addato, Eugene Daphnis, Alessia Di Costanzo, Laura D’Erasmo, Maria Donata Di Taranto, Avishay Ellis, Fabio Fimiani, Giuliana Fortunato, Antonina Giammanco, Marco Gentile, Gabriella Iannuzzo, Meral Kayikcioglu, Genovefa Kolovou, Evangelos Liberopoulos, Karin Littmann, Sergio Martínez-Hervás, Tiziana Montalcini, Fabio Nota, Chiara Pavanello, Livia Pisciotta, Arturo Puja, Giovanni José Real, Jeanine Roeters van Lennep, Joost Rutten, Carlo Sabbà, Tiziana Sampietro, Francesco Sbrana, Kim Steward, Patrizia Suppressa, Fulvio Ventura, Battista Vigna, Anja Vogt, Shahenaz Walji   +59 more
doaj   +1 more source

Lomitapide en hipercolesterolemia familiar heterocigota

Revista Colombiana de Endocrinología, Diabetes y Metabolismo, 2022
Introducción: la hipercolesterolemia familiar (HF) es una enfermedad autosómica dominante causada por mutaciones del gen que codifica el receptor de colesterol de baja densidad (LDLR) o en moléculas asociadas al funcionamiento de este.
Juan Esteban Bedoya Loaiza, Andrés Flórez Romero, Yesid Camilo Hurtado Amézquita   +2 more
doaj   +1 more source